Every 8-K that Janux Therapeutics, Inc. (JANX) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow JANX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full JANX filings page.
Janux Therapeutics, Inc. reported results for the quarter ended June 30, 2026 and provided a clinical update. The company is advancing multiple programs, including JANX007 and JANX014 in metastatic castration-resistant prostate cancer, JANX011 in a Phase 1 healthy volunteer trial, and expects to initiate JANX013 in the second half of 2026.
Collaboration revenue was $10.267 million in the quarter, with a net loss of $21.972 million, compared with a net loss of $33.858 million a year earlier, or $0.35 per share versus $0.55. Cash, cash equivalents and short-term investments totaled $970.9 million as of June 30, 2026, slightly above $966.6 million at December 31, 2025, supporting continued development across the TRACTr, TRACIr and ARM platforms.
Janux Therapeutics, Inc. reported that its Chief Medical Officer, William Go, M.D., Ph.D., departed the company on June 23, 2026. The departure was treated as a termination without “Cause” under Janux’s Change in Control and Severance Benefit Plan.
The company has begun searching for a new Chief Medical Officer. Until a successor is appointed, existing clinical leaders will collectively handle the responsibilities. Janux stated that this transition does not change its development strategy, regulatory plans, or previously disclosed clinical timelines, and that Dr. Go’s departure did not stem from any disagreement over operations, policies, or practices.
Janux Therapeutics, Inc. reported results of its 2026 Annual Meeting of Stockholders held on June 11, 2026. As of the April 17, 2026 record date, 60,961,546 shares of common stock were outstanding, and 53,744,922 shares were present or represented by proxy.
Stockholders elected Class II directors Natasha Hernday and Eric Dobmeier to serve until the 2029 annual meeting. They also ratified Ernst & Young LLP as independent registered public accounting firm for the year ending December 31, 2026, and approved, on an advisory basis, the compensation of named executive officers.
Janux Therapeutics reported first quarter 2026 results, showing a net loss of $24.4 million or $0.39 per share, similar to the prior year. The company ended March 31, 2026 with a strong cash, cash equivalents and short-term investment balance of $956.4 million, supporting its clinical pipeline.
Collaboration revenue was $3.7 million, reflecting progress under partnered programs, including a $35 million milestone from its Bristol Myers Squibb collaboration. Research and development expenses rose modestly to $26.8 million, while general and administrative expenses increased to $11.1 million.
Janux advanced multiple candidates, with JANX007 continuing in a Phase 1b prostate cancer trial, clinical initiation of JANX014, and an ongoing Phase 1 study of JANX011 in healthy volunteers. The company discontinued development of JANX008 after completing Phase 1a and is prioritizing other programs.
Janux Therapeutics, Inc. changed the board class designation of director Eric Dobmeier to rebalance its staggered board. On April 28, 2026, Dobmeier resigned as a Class III director, whose term would have run until the 2027 Annual Meeting of Stockholders, and was immediately reappointed as a Class II director, whose term runs until the 2026 Annual Meeting.
The company states his board service is treated as continuous for all purposes, including vesting and settlement of any outstanding equity awards and other non-employee director compensation. Dobmeier will continue serving on the Board’s Compensation Committee.
Janux Therapeutics filed an 8-K to share fourth-quarter and full-year 2025 results and a business update. The company ended December 31, 2025 with $966.6 million in cash, cash equivalents and short-term investments, down from $1.03 billion a year earlier, providing substantial funding for its pipeline.
Research and development expenses rose to $125.9 million in 2025 from $68.4 million in 2024, while general and administrative expenses were roughly flat at $41.8 million versus $41.0 million. Net loss widened to $157.7 million from $69.0 million, reflecting heavier investment in clinical programs.
Operationally, Janux highlighted continued progress for TRACTr candidates JANX007 in metastatic castration-resistant prostate cancer and JANX008 in solid tumors, as well as the Phase 1 start of JANX011 in healthy volunteers. The company also announced a collaboration and exclusive worldwide license agreement with Bristol Myers Squibb, including $50 million in upfront and near-term milestone payments and the potential for approximately $800 million in additional milestones plus tiered royalties.
Janux Therapeutics entered an exclusive license and collaboration agreement with Bristol-Myers Squibb to develop and commercialize a novel tumor-activated therapeutic for solid tumors. Janux will handle preclinical work through IND submission for one drug candidate, after which BMS will take over global development, manufacturing and commercialization, while Janux supplies product for early clinical trials for a limited period.
Janux receives a $15 million upfront payment and may earn up to $785 million in development, regulatory and sales milestones, including $35 million tied to a near-term milestone. BMS will also pay tiered royalties from high-single digit to low-double digit percentages on annual net sales of any approved products, with royalty terms linked to patent life, regulatory exclusivity and time from first commercial sale.
Janux Therapeutics, Inc. filed a current report to note that it released a press release with its financial results for the three and nine months ended September 30, 2025. The company is furnishing, not filing, this information, which means the press release is not subject to certain liability provisions under the securities laws and is not automatically incorporated into other SEC filings. Investors interested in the detailed revenue, expense, and earnings figures for this period would need to review the attached Exhibit 99.1 press release referenced in the report.
Janux Therapeutics, Inc. reported that Byron Robinson, Ph.D., a previously named executive officer, has left the company. He ceased serving as Chief Strategy Officer and departed effective September 18, 2025. The company determined that his departure qualifies as a termination without “Cause” under its Change in Control and Severance Benefit Plan, which may entitle him to certain severance benefits pursuant to that plan. The filing does not announce any new appointment to the Chief Strategy Officer role.